logo
Book a meeting
InterMune

Inter Mune

Biotechnology, 3280 Bayshore BLVD, Brisbane, California, 94005, United States, 201-500 Employees

intermune.com

  • facebook
  • twitter
  • LinkedIn

phone no Phone Number: +14*********

Who is INTERMUNE

InterMune is a values-driven organization that works to embody integrity, passion, accountability, creativity and teamwork in bringing new treatments and hope to patients and families aro...

Read More

lock icon Get Full Access
map
  • 3280 Bayshore BLVD, Brisbane, California, 94005, United States Headquarters: 3280 Bayshore BLVD, Brisbane, California, 94005, United States
  • 1998 Date Founded: 1998
  • 201-500 Employees: 201-500
  • dollar-icon Revenue: $50 Million to $100 Million
  • tech-icon Active Tech Stack: See technologies
  • Daniel Welch CEO:   Daniel Welch

industries-icon Industry: Biotechnology

SIC SIC Code: 2834 | NAICS Code: 325412 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from INTERMUNE

email-formate-icon
View Email Formats for InterMune
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding InterMune

Answer: InterMune's headquarters are located at 3280 Bayshore BLVD, Brisbane, California, 94005, United States

Answer: InterMune's phone number is +14*********

Answer: InterMune's official website is https://intermune.com

Answer: InterMune's revenue is $50 Million to $100 Million

Answer: InterMune's SIC: 2834

Answer: InterMune's NAICS: 325412

Answer: InterMune has 201-500 employees

Answer: InterMune is in Biotechnology

Answer: InterMune contact info: Phone number: +14********* Website: https://intermune.com

Answer: InterMune is a values-driven organization that works to embody integrity, passion, accountability, creativity and teamwork in bringing new treatments and hope to patients and families around the world. Our focus is research, development and commercialization of innovative therapies in pulmonology and orphan fibrotic diseases, including idiopathic pulmonary fibrosis (IPF), a progressive, irreversible, unpredictable and ultimately fatal lung disease. Pirfenidone, the only medicine approved for IPF, is marketed by InterMune in the EU and Canada as Esbriet and is currently in a Phase 3 clinical trial to support regulatory registration in the United States.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access